Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?

2016 ◽  
Vol 69 (1) ◽  
pp. 20-24 ◽  
Author(s):  
Emad A Rakha ◽  
Marian Pigera ◽  
Sandra J Shin ◽  
Timothy D'Alfonso ◽  
Ian O Ellis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Oestrogen Receptor ◽  
Histological Grade ◽  
Growth Factor Receptor ◽  
Oestrogen Receptor Status ◽  
Repeat Testing ◽  
Epidermal Growth

Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.

2001 ◽  
pp. 175-182 ◽  
Author(s):  
R I Nicholson ◽  
I R Hutcheson ◽  
M E Harper ◽  
J M Knowlden ◽  
D Barrow ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Oestrogen Receptor ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Independent Manner ◽  
Epidermal Growth

There is an increasing body of evidence demonstrating that growth factor networks are highly interactive with oestrogen receptor (ER) signalling in the control of breast cancer growth. As such, tumour responses to anti- hormones are likely to be a composite of the ER and growth factor inhibitory activity of these agents. The current article examines the modulation of growth factor networks during endocrine response, and presents in vitro and clinical evidence that epidermal growth factor receptor signalling, maintained in either an ER-dependent or -independent manner, is critical to anti- hormonal-resistant breast cancer cell growth. The considerable potential of the epidermal growth factor receptor-selective tyrosine kinase inhibitor, ZD 1839 (Iressa; AstraZeneca) to efficiently treat, and perhaps even prevent, endocrine-resistant breast cancer is highlighted.

Sign in / Sign up

Export Citation Format

Share Document